CN1370076A - Hm1.24抗原的表达增强剂 - Google Patents

Hm1.24抗原的表达增强剂 Download PDF

Info

Publication number
CN1370076A
CN1370076A CN00811883A CN00811883A CN1370076A CN 1370076 A CN1370076 A CN 1370076A CN 00811883 A CN00811883 A CN 00811883A CN 00811883 A CN00811883 A CN 00811883A CN 1370076 A CN1370076 A CN 1370076A
Authority
CN
China
Prior art keywords
antibody
cell
myeloma
protein
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00811883A
Other languages
English (en)
Chinese (zh)
Inventor
小阪昌明
尾崎修治
若原裕二
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CN1370076A publication Critical patent/CN1370076A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN00811883A 1999-08-23 2000-08-22 Hm1.24抗原的表达增强剂 Pending CN1370076A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP236007/99 1999-08-23
JP23600799 1999-08-23
JP2000038689 2000-02-16
JP38689/00 2000-02-16

Publications (1)

Publication Number Publication Date
CN1370076A true CN1370076A (zh) 2002-09-18

Family

ID=26532447

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00811883A Pending CN1370076A (zh) 1999-08-23 2000-08-22 Hm1.24抗原的表达增强剂

Country Status (12)

Country Link
US (1) US8287863B2 (enExample)
EP (1) EP1213028B1 (enExample)
JP (1) JP4671570B2 (enExample)
KR (1) KR20020025990A (enExample)
CN (1) CN1370076A (enExample)
AT (1) ATE404216T1 (enExample)
AU (1) AU784460B2 (enExample)
CA (1) CA2382587A1 (enExample)
DE (1) DE60039893D1 (enExample)
ES (1) ES2307526T3 (enExample)
TW (2) TWI248365B (enExample)
WO (1) WO2001013940A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI248365B (en) 1999-08-23 2006-02-01 Chugai Pharmaceutical Co Ltd HM1.24 antigen expression potentiators
JP3986439B2 (ja) 2001-02-07 2007-10-03 中外製薬株式会社 造血器腫瘍の治療剤
EP2208784B1 (en) * 2001-06-22 2013-01-02 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitors containing anti-glypican 3 antibody
US20080219974A1 (en) * 2002-03-01 2008-09-11 Bernett Matthew J Optimized antibodies that target hm1.24
CA2660795C (en) * 2006-09-18 2014-11-18 Xencor, Inc. Optimized antibodies that target hm1.24
WO2010045570A1 (en) * 2008-10-16 2010-04-22 Childerns Hospital Los Angeles Methods and compositions for inhibiting propagation of viruses using recombinant tetherin constructs
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401756A (en) * 1981-04-14 1983-08-30 Immunex Corporation Process for preparing human interleukin 2
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4894227A (en) 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
MX9305855A (es) 1992-09-24 1995-01-31 Tadatsugu Taniguchi Factores 1 y 2 reguladores del interferon en el diagnostico de latumorigenicidad.
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5328989A (en) * 1993-03-05 1994-07-12 Schering-Plough Purification of human interleukin-10 from a cell culture medium
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
US5830463A (en) * 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
TW442493B (en) 1993-10-15 2001-06-23 Toshio Hirano A membrane protein polypeptide having pre-B cell growth-supporting ability and a gene thereof
JP3412930B2 (ja) 1993-10-15 2003-06-03 俊夫 平野 プレｂ細胞増殖支持能を有する膜タンパクポリペプチド及びその遺伝子
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
JP3554355B2 (ja) 1994-03-03 2004-08-18 中外製薬株式会社 Ｉｌ−６オートクライン増殖性ヒト骨髄腫細胞株
EP0770628B9 (en) 1994-07-13 2007-02-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
ATE306930T1 (de) 1994-08-12 2005-11-15 Immunomedics Inc Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
JP3651697B2 (ja) * 1995-03-24 2005-05-25 株式会社アミノアップ化学 新規多糖体物質
WO1996030394A1 (en) 1995-03-31 1996-10-03 Jakob Bohr Method for protein folding
EP0823257B1 (en) * 1995-04-02 2002-08-07 Chugai Seiyaku Kabushiki Kaisha Medicinal composition for curing thrombocytopenia
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
UA76934C2 (en) 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
CA2280875C (en) * 1997-02-12 2005-07-05 Chugai Seiyaku Kabushiki Kaisha Remedies for lymphocytic tumors
EP1023906A4 (en) * 1997-10-14 2005-03-02 Chugai Pharmaceutical Co Ltd AMPLIFIER FOR ANTIBODY AGAINST LYMPHOIDEN TUMOR
TWI248365B (en) 1999-08-23 2006-02-01 Chugai Pharmaceutical Co Ltd HM1.24 antigen expression potentiators
CA2412901A1 (en) 2000-06-22 2001-12-27 Idec Pharmaceutical Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
JP3986439B2 (ja) * 2001-02-07 2007-10-03 中外製薬株式会社 造血器腫瘍の治療剤

Also Published As

Publication number Publication date
US20060193828A1 (en) 2006-08-31
KR20020025990A (ko) 2002-04-04
WO2001013940A1 (en) 2001-03-01
EP1213028A1 (en) 2002-06-12
TW200528127A (en) 2005-09-01
ATE404216T1 (de) 2008-08-15
CA2382587A1 (en) 2001-03-01
TWI290832B (en) 2007-12-11
ES2307526T3 (es) 2008-12-01
EP1213028B1 (en) 2008-08-13
AU784460B2 (en) 2006-04-06
TWI248365B (en) 2006-02-01
DE60039893D1 (enExample) 2008-09-25
US8287863B2 (en) 2012-10-16
AU6598900A (en) 2001-03-19
JP4671570B2 (ja) 2011-04-20
EP1213028A4 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
CN1250381A (zh) 淋巴细胞系肿瘤的治疗剂
CN1259973C (zh) 含有il－6拮抗剂作为有效成分的牛皮癣的预防或治疗剂
CN1289526C (zh) 干细胞因子
CN1874790A (zh) 间皮瘤治疗剂
CN1426423A (zh) 螯合淀粉样蛋白β肽的人源化抗体
CN1551783A (zh) 治疗多发性骨髓瘤的方法
CN1370076A (zh) Hm1.24抗原的表达增强剂
JP3986439B2 (ja) 造血器腫瘍の治療剤
CN1849337A (zh) 利用igsf9和liv－1的、用于治疗癌症的组合物及方法
CN1898260A (zh) 具有抗肥胖活性的肽及其它相关应用
CN1309738C (zh) 抗il－8单克隆抗体、其可变区序列及其应用
CN1275917A (zh) 淋巴细胞肿瘤抗体的增强剂
CN1688695A (zh) 新的树突状细胞共刺激分子
CN1946425A (zh) B细胞疾病的靶
CN1163506C (zh) 新的人细胞因子、其编码序列及用途
JPWO2001013940A1 (ja) Ｈｍ１．２４抗原の発現増強剤
HK1048262A (en) Hm1.24 antigen expression potentiators
JP4522431B2 (ja) 造血器腫瘍の治療剤
CN1172954C (zh) 肝癌高表达基因、其编码的蛋白hcca2及其应用
CN1169832C (zh) 基因p28－II的鉴定与功能研究
HK1026368B (en) Remedies for lymphocytic tumors
HK1047541A (en) Hm1.24 antigen expression potentiators
HK1017364A1 (en) A membrane protein polypeptide having pre-b cell growth-supporting ability and a gene thereof
HK1017364B (en) A membrane protein polypeptide having pre-b cell growth-supporting ability and a gene thereof
CN1903881A (zh) 抗肿瘤多靶点复合抗原及其编码基因与应用

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1048262

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication